Selected research
Industry Research
Therapeutic Proteins and Oral Vaccines Industry Research Report 2026
Market perspective
The global Therapeutic Proteins and Oral Vaccines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Therapeutic Proteins and Oral Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Therapeutic Proteins and Oral Vaccines market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Therapeutic Proteins and Oral Vaccines market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Therapeutic Proteins and Oral Vaccines include Abbott, Sanofi, Merck, Roche, Pfizer, Amgen, TransAlgae, Serum Institute of India and Novo Nordisk, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Therapeutic Proteins and Oral Vaccines market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Therapeutic Proteins and Oral Vaccines.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Therapeutic Proteins and Oral Vaccines Market by Company
Abbott
Sanofi
Merck
Roche
Pfizer
Amgen
TransAlgae
Serum Institute of India
Novo Nordisk
MigVax
Lumen Bioscience
Johnson and Johnson
Emergent Biosolutions
Eli Lilly and Company
Biogen
Therapeutic Proteins and Oral Vaccines Segment by Type
Therapeutic Proteins
Oral Vaccines
Therapeutic Proteins and Oral Vaccines Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Therapeutic Proteins and Oral Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Proteins and Oral Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Proteins and Oral Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Proteins and Oral Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Therapeutic Proteins and Oral Vaccines companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Therapeutic Proteins
- Oral Vaccines
Applications
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Companies covered
- Abbott
- Sanofi
- Merck
- Roche
- Pfizer
- Amgen
- TransAlgae
- Serum Institute of India
- Novo Nordisk
- MigVax
- Lumen Bioscience
- Johnson and Johnson
- Emergent Biosolutions
- Eli Lilly and Company
- Biogen
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Therapeutic Proteins and Oral Vaccines by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Therapeutic Proteins
- 2.2.3 Oral Vaccines
- 2.3 Therapeutic Proteins and Oral Vaccines by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Retail Pharmacies
- 2.3.3 Online Pharmacies
- 2.3.4 Hospital Pharmacies
- 2.4 Assumptions and Limitations
3 Therapeutic Proteins and Oral Vaccines Breakdown Data by Type
- 3.1 Global Therapeutic Proteins and Oral Vaccines Historic Market Size by Type (2021-2026)
- 3.2 Global Therapeutic Proteins and Oral Vaccines Forecasted Market Size by Type (2027-2032)
4 Therapeutic Proteins and Oral Vaccines Breakdown Data by Application
- 4.1 Global Therapeutic Proteins and Oral Vaccines Historic Market Size by Application (2021-2026)
- 4.2 Global Therapeutic Proteins and Oral Vaccines Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Therapeutic Proteins and Oral Vaccines Market Perspective (2021-2032)
- 5.2 Global Therapeutic Proteins and Oral Vaccines Growth Trends by Region
- 5.2.1 Global Therapeutic Proteins and Oral Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Therapeutic Proteins and Oral Vaccines Historic Market Size by Region (2021-2026)
- 5.2.3 Therapeutic Proteins and Oral Vaccines Forecasted Market Size by Region (2027-2032)
- 5.3 Therapeutic Proteins and Oral Vaccines Market Dynamics
- 5.3.1 Therapeutic Proteins and Oral Vaccines Industry Trends
- 5.3.2 Therapeutic Proteins and Oral Vaccines Market Drivers
- 5.3.3 Therapeutic Proteins and Oral Vaccines Market Challenges
- 5.3.4 Therapeutic Proteins and Oral Vaccines Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Therapeutic Proteins and Oral Vaccines Players by Revenue
- 6.1.1 Global Top Therapeutic Proteins and Oral Vaccines Players by Revenue (2021-2026)
- 6.1.2 Global Therapeutic Proteins and Oral Vaccines Revenue Market Share by Players (2021-2026)
- 6.2 Global Therapeutic Proteins and Oral Vaccines Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Therapeutic Proteins and Oral Vaccines Head Office and Area Served
- 6.4 Global Therapeutic Proteins and Oral Vaccines Players, Product Type & Application
- 6.5 Global Therapeutic Proteins and Oral Vaccines Manufacturers Established Date
- 6.6 Global Therapeutic Proteins and Oral Vaccines Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Therapeutic Proteins and Oral Vaccines Market Size (2021-2032)
- 7.2 North America Therapeutic Proteins and Oral Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Therapeutic Proteins and Oral Vaccines Market Size by Country (2021-2026)
- 7.4 North America Therapeutic Proteins and Oral Vaccines Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Therapeutic Proteins and Oral Vaccines Market Size (2021-2032)
- 8.2 Europe Therapeutic Proteins and Oral Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Therapeutic Proteins and Oral Vaccines Market Size by Country (2021-2026)
- 8.4 Europe Therapeutic Proteins and Oral Vaccines Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Therapeutic Proteins and Oral Vaccines Market Size (2021-2032)
- 9.2 Asia-Pacific Therapeutic Proteins and Oral Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Therapeutic Proteins and Oral Vaccines Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Therapeutic Proteins and Oral Vaccines Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Therapeutic Proteins and Oral Vaccines Market Size (2021-2032)
- 10.2 South America Therapeutic Proteins and Oral Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Therapeutic Proteins and Oral Vaccines Market Size by Country (2021-2026)
- 10.4 South America Therapeutic Proteins and Oral Vaccines Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Size (2021-2032)
- 11.2 Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Abbott
- 12.1.1 Abbott Company Information
- 12.1.2 Abbott Business Overview
- 12.1.3 Abbott Revenue in Therapeutic Proteins and Oral Vaccines Business (2021-2026)
- 12.1.4 Abbott Therapeutic Proteins and Oral Vaccines Product Portfolio
- 12.1.5 Abbott Recent Developments
- 12.2 Sanofi
- 12.2.1 Sanofi Company Information
- 12.2.2 Sanofi Business Overview
- 12.2.3 Sanofi Revenue in Therapeutic Proteins and Oral Vaccines Business (2021-2026)
- 12.2.4 Sanofi Therapeutic Proteins and Oral Vaccines Product Portfolio
- 12.2.5 Sanofi Recent Developments
- 12.3 Merck
- 12.3.1 Merck Company Information
- 12.3.2 Merck Business Overview
- 12.3.3 Merck Revenue in Therapeutic Proteins and Oral Vaccines Business (2021-2026)
- 12.3.4 Merck Therapeutic Proteins and Oral Vaccines Product Portfolio
- 12.3.5 Merck Recent Developments
- 12.4 Roche
- 12.4.1 Roche Company Information
- 12.4.2 Roche Business Overview
- 12.4.3 Roche Revenue in Therapeutic Proteins and Oral Vaccines Business (2021-2026)
- 12.4.4 Roche Therapeutic Proteins and Oral Vaccines Product Portfolio
- 12.4.5 Roche Recent Developments
- 12.5 Pfizer
- 12.5.1 Pfizer Company Information
- 12.5.2 Pfizer Business Overview
- 12.5.3 Pfizer Revenue in Therapeutic Proteins and Oral Vaccines Business (2021-2026)
- 12.5.4 Pfizer Therapeutic Proteins and Oral Vaccines Product Portfolio
- 12.5.5 Pfizer Recent Developments
- 12.6 Amgen
- 12.6.1 Amgen Company Information
- 12.6.2 Amgen Business Overview
- 12.6.3 Amgen Revenue in Therapeutic Proteins and Oral Vaccines Business (2021-2026)
- 12.6.4 Amgen Therapeutic Proteins and Oral Vaccines Product Portfolio
- 12.6.5 Amgen Recent Developments
- 12.7 TransAlgae
- 12.7.1 TransAlgae Company Information
- 12.7.2 TransAlgae Business Overview
- 12.7.3 TransAlgae Revenue in Therapeutic Proteins and Oral Vaccines Business (2021-2026)
- 12.7.4 TransAlgae Therapeutic Proteins and Oral Vaccines Product Portfolio
- 12.7.5 TransAlgae Recent Developments
- 12.8 Serum Institute of India
- 12.8.1 Serum Institute of India Company Information
- 12.8.2 Serum Institute of India Business Overview
- 12.8.3 Serum Institute of India Revenue in Therapeutic Proteins and Oral Vaccines Business (2021-2026)
- 12.8.4 Serum Institute of India Therapeutic Proteins and Oral Vaccines Product Portfolio
- 12.8.5 Serum Institute of India Recent Developments
- 12.9 Novo Nordisk
- 12.9.1 Novo Nordisk Company Information
- 12.9.2 Novo Nordisk Business Overview
- 12.9.3 Novo Nordisk Revenue in Therapeutic Proteins and Oral Vaccines Business (2021-2026)
- 12.9.4 Novo Nordisk Therapeutic Proteins and Oral Vaccines Product Portfolio
- 12.9.5 Novo Nordisk Recent Developments
- 12.10 MigVax
- 12.10.1 MigVax Company Information
- 12.10.2 MigVax Business Overview
- 12.10.3 MigVax Revenue in Therapeutic Proteins and Oral Vaccines Business (2021-2026)
- 12.10.4 MigVax Therapeutic Proteins and Oral Vaccines Product Portfolio
- 12.10.5 MigVax Recent Developments
- 12.11 Lumen Bioscience
- 12.11.1 Lumen Bioscience Company Information
- 12.11.2 Lumen Bioscience Business Overview
- 12.11.3 Lumen Bioscience Revenue in Therapeutic Proteins and Oral Vaccines Business (2021-2026)
- 12.11.4 Lumen Bioscience Therapeutic Proteins and Oral Vaccines Product Portfolio
- 12.11.5 Lumen Bioscience Recent Developments
- 12.12 Johnson and Johnson
- 12.12.1 Johnson and Johnson Company Information
- 12.12.2 Johnson and Johnson Business Overview
- 12.12.3 Johnson and Johnson Revenue in Therapeutic Proteins and Oral Vaccines Business (2021-2026)
- 12.12.4 Johnson and Johnson Therapeutic Proteins and Oral Vaccines Product Portfolio
- 12.12.5 Johnson and Johnson Recent Developments
- 12.13 Emergent Biosolutions
- 12.13.1 Emergent Biosolutions Company Information
- 12.13.2 Emergent Biosolutions Business Overview
- 12.13.3 Emergent Biosolutions Revenue in Therapeutic Proteins and Oral Vaccines Business (2021-2026)
- 12.13.4 Emergent Biosolutions Therapeutic Proteins and Oral Vaccines Product Portfolio
- 12.13.5 Emergent Biosolutions Recent Developments
- 12.14 Eli Lilly and Company
- 12.14.1 Eli Lilly and Company Company Information
- 12.14.2 Eli Lilly and Company Business Overview
- 12.14.3 Eli Lilly and Company Revenue in Therapeutic Proteins and Oral Vaccines Business (2021-2026)
- 12.14.4 Eli Lilly and Company Therapeutic Proteins and Oral Vaccines Product Portfolio
- 12.14.5 Eli Lilly and Company Recent Developments
- 12.15 Biogen
- 12.15.1 Biogen Company Information
- 12.15.2 Biogen Business Overview
- 12.15.3 Biogen Revenue in Therapeutic Proteins and Oral Vaccines Business (2021-2026)
- 12.15.4 Biogen Therapeutic Proteins and Oral Vaccines Product Portfolio
- 12.15.5 Biogen Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst